CREBBP and neoplasm: Selective antagonists of CBP/β-catenin have demonstrated to be effective in several preclinical tumor models, safely eliminating quiescent cancer stem cells (CSCs) without damaging multipotent somatic stem cells (SSCs) [44,45,46].